Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDMETH: Methotrexate vs prednisone as first-line therapy for pulmonary sarcoidosis
2019-004148-31Phase 4Active
- Sponsor
- Erasmus Medical Center Department of Pulmonology
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in pulmonary sarcoidosis comparing Methotrexate first-line with Prednisone first-line (2 arms). Primary endpoint: Change in forced vital capacity (FVC). Started Nov 2019; status: active.
02
Drugs
methotrexateprednisone
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2019-004148-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004148-31.